NasdaqCM - Nasdaq Real Time Price USD

SeaStar Medical Holding Corporation (ICU)

1.2700

+0.0780

+(6.54%)

At close: June 6 at 4:00:00 PM EDT

1.2312

-0.04

(-3.06%)

After hours: June 6 at 6:49:33 PM EDT

SeaStar Q1 Results: QUELIMMUNE Sales Up Fourfold Sequentially, Company Now Targeting Adult Market

By Meg Flippin Benzinga DETROIT, MICHIGAN - May 29, 2025 (NEWMEDIAWIRE) - SeaStar Medical Holding Corporation (NASDAQ: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and...

NewMediaWire 10 days ago

ICU
+6.54%

ICUCW
SeaStar Medical Announces CMS Coverage for Medicare and Medicaid Eligible Patients with Cardiorenal Syndrome Awaiting LVAD in Investigational Trial of SCD Therapy

Coverage marks SeaStar Medical’s second award by CMS for reimbursement of medical expenses for Medicare and Medicaid patients in a clinical trial Stands out as rare award with less than 100 clinical trials covered annually DENVER, May 28, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that the U.S. Cente

GlobeNewswire 11 days ago

ICU
+6.54%

ICUCW
SeaStar Medical Holding Corp (ICU) Q1 2025 Earnings Call Highlights: Revenue Surge and ...

SeaStar Medical Holding Corp (ICU) reports a fourfold revenue increase, new FDA designations, and significant market opportunities in its latest earnings call.

GuruFocus.com 24 days ago

ICUCW
SeaStar Medical Reports First Quarter 2025 Financial Results and Provides Business Updates

QUELIMMUNE adoption drives four-fold increase in sequential quarter net revenue NEUTRALIZE AKI trial exceeds 50% enrollment, triggers start of Interim AnalysisWebcast Today at 4:30 pm Eastern Time DENVER, May 14, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today financial results for the three months ended Ma

GlobeNewswire 25 days ago

ICU
+6.54%

ICUCW
SeaStar Medical Reaches Interim Enrollment Target for NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury

Indication Has Been Granted FDA Breakthrough Device Designation for Potential PMA FilingDENVER, May 13, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it has successfully reached the halfway point in the NEUTRALIZE-AKI pivotal clinical trial, enabling a per protocol prespecified interim analysis by

GlobeNewswire 26 days ago

ICU
+6.54%

ICUCW
SeaStar Medical to Report First Quarter Financial Results on May 14, 2025

DENVER, May 07, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its first quarter financial results after market close on Wednesday, May 14, 2025, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Wednesday, May 14, 2025, at 4:30 p

GlobeNewswire last month

ICU
+6.54%

ICUCW
SeaStar Medical Announces CEO Interview on Benzinga All Access to Occur Today at Approximately 10:50 am Eastern Time

DENVER, April 30, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today that Eric Schlorff, CEO of SeaStar Medical, will be a featured guest today, Wednesday, April 30th, at approximately 10:50 am Eastern Time on the Benzinga All Access Show. The event will be broadcast live and can be viewed at https://youtube.

GlobeNewswire last month

ICU
+6.54%

ICUCW
FDA Grants SeaStar Medical Two New Breakthrough Device Designations for SCD Therapy to Treat Systemic Inflammatory Response in Adult and Pediatric Patients Undergoing Cardiac Surgery

DENVER, April 08, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that the U.S. Food and Drug Administration (FDA) has granted SeaStar Medical two new Breakthrough Device Designations for its Selective Cytopheretic Device (SCD) therapy. The two new Breakthrough Device Designations are indicated for the tr

GlobeNewswire last month

ICU
+6.54%

ICUCW
SeaStar Medical Holding Corp (ICU) Q4 2024 Earnings Call Highlights: Strategic Advances Amidst ...

SeaStar Medical Holding Corp (ICU) navigates a pivotal year with significant product launches, clinical trial progress, and financial restructuring.

GuruFocus.com 2 months ago

ICUCW
SeaStar Medical Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Webcast Today at 4:30 pm Eastern TimeDENVER, March 27, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today financial results for the three months and year ended December 31, 2024, and provided business updates on key initiatives. “Our significant accomplishment in 2024 position us well for a transformational y

GlobeNewswire 2 months ago

ICU
+6.54%

ICUCW
SeaStar Medical to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

DENVER, March 24, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its fourth quarter and year-end 2024 financial results after market close on Thursday, March 27, 2025, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Thursday, Ma

GlobeNewswire 2 months ago

ICU
+6.54%

ICUCW
NKF Honors SeaStar Medical, with 2025 Corporate Innovator Award

SeaStar Medical (Nasdaq: ICU) has been selected to receive the 2025 Corporate Innovator Award from the National Kidney Foundation (NKF) at the 2025 Spring Clinical Meetings in Boston.

PR Newswire 2 months ago

ICU
+6.54%

ICUCW
SeaStar Medical Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market

DENVER, Feb. 03, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) today announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rule, with a single institutional investor for the issuance and sale of an aggregate of 3,529,412 shares of its common stock (or pre-funded warrants in lieu thereof). In a concurrent private placement, the Company issued and sold to the investor warrants to purchase up to

GlobeNewswire 4 months ago

ICU
+6.54%

ICUCW
SeaStar Medical Announces $6 Million Registered Direct Offering Priced At-the-Market

DENVER, Jan. 31, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) today announced it has entered into a securities purchase agreement with a single institutional investor for the issuance and sale of an aggregate of 3,529,412 shares of its common stock (or pre-funded warrants in lieu thereof) in a registered direct offering. In a concurrent private placement, the Company also agreed to issue and sell to the investor warrants to purchase up to an aggreg

GlobeNewswire 4 months ago

ICU
+6.54%

ICUCW
SeaStar Medical Adds Fifth Hospital Customer for QUELIMMUNE

DENVER, Jan. 27, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage therapeutic medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, has shipped QUELIMMUNE™ to a California medical center recognized as a world leader in pediatric research and treatments, increasing commercial customers to five. QUELIMMUNE is the company’s Selective Cytopheretic Device (SCD) for treating critically ill

GlobeNewswire 4 months ago

ICU
+6.54%

ICUCW
Mayo Clinic joins SeaStar Medical for acute kidney injury trial

The trial aims to enrol 200 adult subjects.

Medical Device Network 4 months ago

ICUCW
SeaStar Medical Activates 15th Site for its Adult Acute Kidney Injury Pivotal Trial

DENVER, Jan. 22, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that Mayo Clinic is now cleared to enroll subjects in the company’s NEUTRALIZE-AKI pivotal trial, increasing the number of activated sites to 15. “We are thrilled to activate another large academic center to our study,” said Kevin Chung, MD, Chief Medical O

GlobeNewswire 4 months ago

ICU
+6.54%

ICUCW
SeaStar Medical says FDA approves feasibility study with SCD-ADULT

SeaStar Medical (ICU) announced that the U.S. FDA has approved an investigational device exemption application to evaluate the safety and initial efficacy of SeaStar Medical’s Selective Cytopheretic Device, or SCD-ADULT, in reducing inflammation in adult patients with acute heart failure with worsening renal function due to cardiorenal syndrome or severe right ventricular failure awaiting a left ventricular assist device implantation. This feasibility study is expected to enroll 20 patients at u

TipRanks 4 months ago

ICU
+6.54%

ICUCW
FDA Approves Feasibility Study with SeaStar Medical’s Selective Cytopheretic Device in Adults with Cardiorenal Syndrome

Study to be conducted under $3.6 million NIH grant DENVER, Jan. 13, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) application to evaluate the safety and initial efficacy of SeaStar Medical’s Selective Cytopheretic De

GlobeNewswire 4 months ago

ICU
+6.54%

ICUCW
SeaStar Medical Begins Shipping QUELIMMUNE to a Fourth Hospital Customer

DENVER, Jan. 08, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the shipment of its QUELIMMUNE™ device to a prominent academic medical center, representing SeaStar Medical’s fourth commercial customer. QUELIMMUNE is the company’s Selective Cytopheretic Device (SCD) for treating critically ill children in the intensive c

GlobeNewswire 4 months ago

ICU
+6.54%

ICUCW

Performance Overview

Return	ICU	S&P 500 (^GSPC)
YTD	-34.54%	+2.02%
1-Year	-76.37%	+12.09%
3-Year	-99.50%	+45.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

SeaStar Medical Holding Corporation (ICU)

SeaStar Q1 Results: QUELIMMUNE Sales Up Fourfold Sequentially, Company Now Targeting Adult Market

SeaStar Medical Announces CMS Coverage for Medicare and Medicaid Eligible Patients with Cardiorenal Syndrome Awaiting LVAD in Investigational Trial of SCD Therapy

SeaStar Medical Holding Corp (ICU) Q1 2025 Earnings Call Highlights: Revenue Surge and ...

SeaStar Medical Reports First Quarter 2025 Financial Results and Provides Business Updates

SeaStar Medical Reaches Interim Enrollment Target for NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury

SeaStar Medical to Report First Quarter Financial Results on May 14, 2025

SeaStar Medical Announces CEO Interview on Benzinga All Access to Occur Today at Approximately 10:50 am Eastern Time

FDA Grants SeaStar Medical Two New Breakthrough Device Designations for SCD Therapy to Treat Systemic Inflammatory Response in Adult and Pediatric Patients Undergoing Cardiac Surgery

SeaStar Medical Holding Corp (ICU) Q4 2024 Earnings Call Highlights: Strategic Advances Amidst ...

SeaStar Medical Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

SeaStar Medical to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

NKF Honors SeaStar Medical, with 2025 Corporate Innovator Award

SeaStar Medical Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market

SeaStar Medical Announces $6 Million Registered Direct Offering Priced At-the-Market

SeaStar Medical Adds Fifth Hospital Customer for QUELIMMUNE

Mayo Clinic joins SeaStar Medical for acute kidney injury trial

SeaStar Medical Activates 15th Site for its Adult Acute Kidney Injury Pivotal Trial

SeaStar Medical says FDA approves feasibility study with SCD-ADULT

FDA Approves Feasibility Study with SeaStar Medical’s Selective Cytopheretic Device in Adults with Cardiorenal Syndrome

SeaStar Medical Begins Shipping QUELIMMUNE to a Fourth Hospital Customer

Performance Overview